Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
GENE:
MDM4 (The mouse double minute 4)
i
Other names:
MDM4, The mouse double minute 4, MDM4 Regulator Of P53, Mdm2-Like P53-Binding Protein, MDM4, P53 Regulator, Double Minute 4, Human Homolog Of; P53-Binding Protein, P53-Binding Protein Mdm4, Double Minute 4 Protein
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4194
Related tests:
‹
OncoGuide™ NCC Oncopanel System
TheraSure™-CNI MONITOR Assay
OncoGuide™ NCC Oncopanel System
TheraSure™-CNI MONITOR Assay
›
Associations
(10)
News
Trials
VERI cancer hierarchy
Reset Filters
EGFR mutation + MDM4 *32C>A
Lung Adenocarcinoma
EGFR mutation + MDM4 *32C>A
Lung Adenocarcinoma
gefitinib
Sensitive: C3 – Early Trials
gefitinib
Sensitive
:
C3
gefitinib
Sensitive: C3 – Early Trials
gefitinib
Sensitive
:
C3
MDM4 amplification
Mucosal Melanoma
MDM4 amplification
Mucosal Melanoma
ipilimumab
Resistant: C3 – Early Trials
ipilimumab
Resistant
:
C3
ipilimumab
Resistant: C3 – Early Trials
ipilimumab
Resistant
:
C3
MDM4 amplification
Mucosal Melanoma
MDM4 amplification
Mucosal Melanoma
nivolumab + ipilimumab
Resistant: C3 – Early Trials
nivolumab + ipilimumab
Resistant
:
C3
nivolumab + ipilimumab
Resistant: C3 – Early Trials
nivolumab + ipilimumab
Resistant
:
C3
MDM4 amplification
Mucosal Melanoma
MDM4 amplification
Mucosal Melanoma
nivolumab
Resistant: C3 – Early Trials
nivolumab
Resistant
:
C3
nivolumab
Resistant: C3 – Early Trials
nivolumab
Resistant
:
C3
MDM4 amplification
Mucosal Melanoma
MDM4 amplification
Mucosal Melanoma
pembrolizumab
Resistant: C3 – Early Trials
pembrolizumab
Resistant
:
C3
pembrolizumab
Resistant: C3 – Early Trials
pembrolizumab
Resistant
:
C3
HK2 overexpression
Colorectal Cancer
HK2 overexpression
Colorectal Cancer
cetuximab
Sensitive: C3 – Early Trials
cetuximab
Sensitive
:
C3
cetuximab
Sensitive: C3 – Early Trials
cetuximab
Sensitive
:
C3
MDM4 amplification
Gastric Adenocarcinoma
MDM4 amplification
Gastric Adenocarcinoma
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
MDM4 mutation
Non Small Cell Lung Cancer
MDM4 mutation
Non Small Cell Lung Cancer
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
MDM4 mutation
HER2 Positive Breast Cancer
MDM4 mutation
HER2 Positive Breast Cancer
TCbHP
Resistant: C3 – Early Trials
TCbHP
Resistant
:
C3
TCbHP
Resistant: C3 – Early Trials
TCbHP
Resistant
:
C3
HK2 overexpression
Acute Myelogenous Leukemia
HK2 overexpression
Acute Myelogenous Leukemia
daunorubicin
Resistant: D – Preclinical
daunorubicin
Resistant
:
D
daunorubicin
Resistant: D – Preclinical
daunorubicin
Resistant
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.